

Natalia Buza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2398388/publications.pdf>

Version: 2024-02-01

100
papers

3,205
citations

159585

30
h-index

182427

51
g-index

103
all docs

103
docs citations

103
times ranked

3471
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma: Implications for Clinical HER2 Testing and Interpretation. Archives of Pathology and Laboratory Medicine, 2023, 147, 331-337.	2.5	4
2	HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma. International Journal of Gynecological Pathology, 2022, 41, 132-141.	1.4	11
3	Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors. Seminars in Diagnostic Pathology, 2022, 39, 58-77.	1.5	10
4	Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecologic Oncology Reports, 2022, 39, 100913.	0.6	2
5	Randomised phase II trial of weekly ixabepilone±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal of Cancer, 2022, 126, 1695-1703.	6.4	5
6	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer, 2022, 128, 1206-1218.	4.1	28
7	HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand. Archives of Pathology and Laboratory Medicine, 2021, 145, 687-691.	2.5	50
8	Intraoperative Consultation. , 2021, , 317-343.		0
9	Gestational Trophoblastic Diseases. , 2021, , 173-191.		0
10	Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study. Modern Pathology, 2021, 34, 1194-1202.	5.5	24
11	Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	48
12	A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).. Journal of Clinical Oncology, 2021, 39, 5523-5523.	1.6	5
13	Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine. Modern Pathology, 2021, 34, 1658-1672.	5.5	17
14	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology, 2021, 163, 334-341.	1.4	10
15	Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. Human Pathology, 2021, 118, 1-8.	2.0	6
16	Immunohistochemistry. , 2021, , 367-416.		0
17	Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. International Journal of Gynecological Pathology, 2021, 40, 263-271.	1.4	16
18	HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. International Journal of Gynecological Pathology, 2021, 40, 17-23.	1.4	25

#	ARTICLE	IF	CITATIONS
19	HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. <i>Modern Pathology</i> , 2020, 33, 118-127.	5.5	53
20	Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). <i>Gynecologic Oncology</i> , 2020, 157, 161-166.	1.4	106
21	Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients. <i>Modern Pathology</i> , 2020, 33, 1172-1181.	5.5	23
22	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656.	4.6	20
23	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 430-438.	1.4	18
24	Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. <i>Gynecologic Oncology</i> , 2020, 159, 17-22.	1.4	42
25	Lack of genetic homozygosity in prepubertal teratomas: divergent pathogenesis distinct from that of teratomas in adolescents. <i>Laboratory Investigation</i> , 2020, 100, 1447-1454.	3.7	4
26	Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. <i>Modern Pathology</i> , 2020, 33, 1979-1988.	5.5	20
27	Molecular and clinicopathologic characterization of intravenous leiomyomatosis. <i>Modern Pathology</i> , 2020, 33, 1844-1860.	5.5	16
28	Genital tuberculosis screening at an academic fertility center in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 737.e1-737.e10.	1.3	17
29	Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100554.	0.6	3
30	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 118.	2.8	30
31	Randomized Phase II Trial of Carboplatin+Paclitaxel Compared with Carboplatin+Paclitaxel+Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 3928-3935.	7.0	154
32	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020, 10, 973.	3.3	31
33	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570.	1.8	32
34	Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6084-6084.	1.6	1
35	Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	3
36	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	7.1	52

#	ARTICLE	IF	CITATIONS
37	Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women. <i>Modern Pathology</i> , 2019, 32, 1271-1280.	5.5	17
38	Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. <i>Modern Pathology</i> , 2019, 32, 1180-1188.	5.5	15
39	Ovarian Teratomas in Women With Anti-N-methyl-D-Aspartate Receptor Encephalitis. <i>American Journal of Surgical Pathology</i> , 2019, 43, 949-964.	3.7	19
40	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	7.1	49
41	Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. <i>Modern Pathology</i> , 2019, 32, 650-658.	5.5	37
42	Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 47-64.	2.5	27
43	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17028-e17028.	1.6	1
44	Intraoperative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes. <i>Histopathology</i> , 2018, 73, 109-123.	2.9	9
45	<i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1003-1011.	4.1	25
46	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. <i>Clinical Cancer Research</i> , 2018, 24, 3282-3291.	7.0	44
47	Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2018, 23, 28-33.	0.6	4
48	KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. <i>Modern Pathology</i> , 2018, 31, 350-357.	5.5	7
49	Endometrial Carcinoma With Trophoblastic Components: Clinicopathologic Analysis of a Rare Entity. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 174-190.	1.4	24
50	FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors: Genotype-Phenotype Correlation With Diagnostic Considerations. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 305-315.	1.4	31
51	Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. <i>Journal of Clinical Oncology</i> , 2018, 36, 2044-2051.	1.6	313
52	Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score. <i>Breast Journal</i> , 2018, 24, 976-980.	1.0	14
53	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853.	7.0	18
54	Hydatidiform Moles: Genetic Basis and Precision Diagnosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 449-485.	22.4	91

#	ARTICLE	IF	CITATIONS
55	Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model. <i>Scientific Reports</i> , 2017, 7, 40989.	3.3	18
56	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. <i>Gynecologic Oncology</i> , 2017, 146, 179-186.	1.4	37
57	Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1). <i>Gynecologic Oncology Reports</i> , 2017, 19, 10-12.	0.6	14
58	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152.	1.4	18
59	Immunohistochemistry in Gynecologic Pathology: An Example-Based Practical Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1052-1071.	2.5	20
60	Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 101-106.	1.4	12
61	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. <i>Clinical Cancer Research</i> , 2017, 23, 5836-5845.	7.0	51
62	Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis. <i>Modern Pathology</i> , 2017, 30, 1467-1475.	5.5	22
63	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14009-e14009.	1.6	1
64	Ancillary studies for precision diagnosis of hydatidiform moles. <i>Diagnostic Histopathology</i> , 2017, 23, 292-302.	0.4	0
65	Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study. <i>Histopathology</i> , 2016, 69, 383-392.	2.9	13
66	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12238-12243.	7.1	181
67	Regression of Chemotherapy-Resistant Polymerase β (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. <i>Clinical Cancer Research</i> , 2016, 22, 5682-5687.	7.0	145
68	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1900-1909.	4.1	55
69	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. <i>British Journal of Cancer</i> , 2016, 115, 303-311.	6.4	27
70	Putative Precursor Lesions of Gestational Trophoblastic Neoplasia. , 2016, , 85-102.		0
71	Mismatch repair deficiency testing in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 591-604.	3.1	66
72	Ovarian Sertoli Leydig cell tumors: a single institution series of predominantly postmenopausal women.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17052-e17052.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Grading of atypia in genital skin lesions: routine microscopic evaluation and use of p16 immunostaining. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 519-526.	1.3	5
74	Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. <i>Human Pathology</i> , 2015, 46, 1000-1005.	2.0	11
75	T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 29-38.	3.3	51
76	Intravenous Leiomyomatosis Revisited. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 169-176.	1.4	40
77	Intrauterine Pregnancy and Gestational Trophoblastic Disease. , 2015, , 141-149.		0
78	HER2 as Biomarker for Endometrial Cancer Epidermal growth factor receptor-2 HER2. <i>Biomarkers in Disease</i> , 2015, , 507-526.	0.1	0
79	Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium. <i>Modern Pathology</i> , 2014, 27, 675-680.	5.5	39
80	HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 343-350.	2.5	120
81	Egg Donor Pregnancy. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 507-510.	1.4	18
82	Genotyping Diagnosis of Nongestational Choriocarcinoma Involving Fallopian Tube and Broad Ligament. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 58-63.	1.4	14
83	Mitotically Active Microglandular Hyperplasia of the Cervix. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 524-530.	1.4	18
84	Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability. <i>Human Pathology</i> , 2014, 45, 549-555.	2.0	23
85	Ancillary Techniques to Refine Diagnosis of GTD. <i>Current Obstetrics and Gynecology Reports</i> , 2014, 3, 65-75.	0.8	0
86	Class III β -tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 101-110.	3.3	40
87	An unexpected mass of the urachus: a case report. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, e1-e3.	1.3	11
88	Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study. <i>Human Pathology</i> , 2014, 45, 1885-1892.	2.0	39
89	Immunohistochemistry and other ancillary techniques in the diagnosis of gestational trophoblastic diseases. <i>Seminars in Diagnostic Pathology</i> , 2014, 31, 223-232.	1.5	38
90	HER2 as Biomarker for Endometrial Cancer. , 2014, , 1-16.		0

#	ARTICLE	IF	CITATIONS
91	Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. <i>Modern Pathology</i> , 2013, 26, 1605-1612.	5.5	125
92	Class III β -tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 62.e1-62.e9.	1.3	26
93	Tubulin β overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. <i>Cancer</i> , 2013, 119, 2582-2592.	4.1	43
94	Partial Hydatidiform Mole. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 307-315.	1.4	50
95	Marked heterogeneity of <i>HER2/NEU</i> gene amplification in endometrial serous carcinoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1178-1186.	2.8	56
96	Urinary hCG Screening in the Gynecologic Oncology Population. <i>Journal of Gynecologic Surgery</i> , 2011, 27, 143-146.	0.1	0
97	Myoepithelial carcinoma of the breast: a clinicopathological and immunohistochemical study of 15 diagnostically challenging cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 337-345.	2.8	32
98	Gestational trophoblastic disease: histopathological diagnosis in the molecular era. <i>Diagnostic Histopathology</i> , 2010, 16, 526-537.	0.4	24
99	Inverse p16 and p63 Expression in Small Cell Carcinoma and High-Grade Urothelial Cell Carcinoma of the Urinary Bladder. <i>International Journal of Surgical Pathology</i> , 2010, 18, 94-102.	0.8	36
100	Comparative Analysis of P16 and P53 Expression in Uterine Malignant Mixed Mullerian Tumors. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 514-521.	1.4	27